Neurogene Inc - Asset Resilience Ratio
Neurogene Inc (NGNE) has an Asset Resilience Ratio of 57.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Neurogene Inc (NGNE) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Neurogene Inc's Asset Resilience Ratio has changed over time. See NGNE total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Neurogene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Neurogene Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $165.17 Million | 57.12% |
| Total Liquid Assets | $165.17 Million | 57.12% |
Asset Resilience Insights
- Very High Liquidity: Neurogene Inc maintains exceptional liquid asset reserves at 57.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Neurogene Inc Industry Peers by Asset Resilience Ratio
Compare Neurogene Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Neurogene Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Neurogene Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.23% | $165.17 Million | $288.60 Million | +4.86pp |
| 2024-12-31 | 52.37% | $175.82 Million | $335.73 Million | +30.38pp |
| 2023-12-31 | 21.99% | $48.95 Million | $222.57 Million | -31.55pp |
| 2022-12-31 | 53.54% | $58.50 Million | $109.27 Million | +2.73pp |
| 2017-12-31 | 50.81% | $56.05 Million | $110.33 Million | +4.97pp |
| 2016-12-31 | 45.83% | $70.76 Million | $154.38 Million | +14.99pp |
| 2015-12-31 | 30.84% | $34.96 Million | $113.34 Million | -27.56pp |
| 2014-12-31 | 58.40% | $24.19 Million | $41.42 Million | +53.60pp |
| 2013-12-31 | 4.80% | $2.82 Million | $58.77 Million | -- |
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more